HOME >> BIOLOGY >> NEWS
Yearling horse auction to benefit equine research

Middleburg, Va., Oct. 1, 2004 -- Sale of Virginia Tech's yearling horses at the Middleburg Agricultural Research and Extension Center, Sunday, Oct. 10, will give horse enthusiasts the opportunity to acquire some of the finest horses in the state and support continued research to improve the horse industry. The sale of yearlings begins with inspections at 10 a.m. and the auction begins at 2 p.m.

"Our 2004 auction will feature yearlings registered with the Jockey Club and the Virginia Thoroughbred Breeders Association," said James Bowen, interim director of the Middleburg center. The yearlings have been bred and cared for as part of the research program at the Center.

Yearlings sold at previous sales have matured to show, hunt, race, and jump. This year's sale includes a granddaughter of Secretariat whose half siblings have won close to $450,000. Many of the yearlings in the sale were sired by Ball's Bluff, a stallion at the center who was named Virginia's leading sprint sire based on earnings for 2004 with total earnings reaching more than $620,000. For example, recently Bluffie Slew, which was sold at a previous auction, a filly by Ball's Bluff out of Our Lady Slew, was first in the Brookmeade Stakes race at Colonial Downs.

"The Center has approximately 45 Thoroughbred broodmares who produce between 25 and 30 foals annually. The growing foals provide researchers an opportunity to study how nutrition affects metabolism and skeletal development," said W. Burton Staniar, assistant professor of equine nutrition.

The Middleburg center's pasture-based equine nutrition research relates the care and welfare of the horse from conception through its older years to its interaction as a grazing animal with the land.

The research objectives are to develop pastures and pasture supplements that improve the reproductive efficiency of mares, optimize growth in the young horses, enhance athletic performance, and protect and improve the land and
'"/>

Contact: Mary Ann Johnson
jnayram@vt.edu
540-231-6975
Virginia Tech
1-Oct-2004


Page: 1 2

Related biology news :

1. A private bandwidth for communication in bats: Evidence from insular horseshoe bats
2. Fat horses face health problems
3. Vets seeing more horses with nutritional issues this year
4. Trojan horse strategy defeats drug-resistant bacteria
5. Composting may be alternative in wake of horse slaughter bill
6. Witonsky honored with Pfizer award for work with EPM disease in horses
7. Heavy horseriders theyre a pain in the back!
8. Basque Country horses
9. Virginia Tech researcher examining malignant melanoma in horses
10. Study shows how respiratory disorder slows some racehorses
11. Ancient DNA helps clarify the origins of two extinct New World horse species

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Yearling horse auction benefit equine research

(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: